Forskning ved Københavns Universitet - Københavns Universitet

Forside

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. / Boesen, Kim; Saiz, Luis Carlos; Erviti, Juan; Storebø, Ole Jakob; Gluud, Christian; Gøtzsche, Peter C; Jørgensen, Karsten Juhl.

I: Evidence - Based Medicine, Bind 22, Nr. 4, 2017, s. 143-147.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Boesen, K, Saiz, LC, Erviti, J, Storebø, OJ, Gluud, C, Gøtzsche, PC & Jørgensen, KJ 2017, 'The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder' Evidence - Based Medicine, bind 22, nr. 4, s. 143-147. https://doi.org/10.1136/ebmed-2017-110716

APA

Boesen, K., Saiz, L. C., Erviti, J., Storebø, O. J., Gluud, C., Gøtzsche, P. C., & Jørgensen, K. J. (2017). The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evidence - Based Medicine, 22(4), 143-147. https://doi.org/10.1136/ebmed-2017-110716

Vancouver

Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC o.a. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evidence - Based Medicine. 2017;22(4):143-147. https://doi.org/10.1136/ebmed-2017-110716

Author

Boesen, Kim ; Saiz, Luis Carlos ; Erviti, Juan ; Storebø, Ole Jakob ; Gluud, Christian ; Gøtzsche, Peter C ; Jørgensen, Karsten Juhl. / The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. I: Evidence - Based Medicine. 2017 ; Bind 22, Nr. 4. s. 143-147.

Bibtex

@article{4e3420eddba84ce5926eef74ff6ee24b,
title = "The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder",
abstract = "A Cochrane systematic review on immediate-release methylphenidate for adults with attention deficit hyperactivity disorder (ADHD) was withdrawn from the Cochrane Library on 26 May 2016 after substantial criticism of its methods and flawed conclusions. Retraction of scientific papers on this basis is unusual but can be necessary. We provide a summary of the criticism that led to the withdrawal. We detail the methodological flaws of the withdrawn Cochrane systematic review and general issues of bias and shortcomings of the included ADHD trials: cross-over designs compared with parallel-group designs, exclusion of participants with psychiatric comorbidity, absence of 'functional outcomes' and use of clinical outcomes with limited relevance, short trial duration and small trial populations, broken blinding caused by easily recognisable side effects, combining outcome assessments by trial investigators and participants, outcome reporting bias, poor evaluation of cardiovascular and psychiatric harms and conflicts of interest of trialists and systematic reviewers. The withdrawal of the Cochrane systematic review signals recognition of previous unreliable clinical ADHD research. We conclude that clinical trials of immediate-release methylphenidate in adults with ADHD are of very low quality. We urgently need well-conducted long-term trials free of bias to assess the benefits and harms of central stimulant treatment in adult ADHD.",
author = "Kim Boesen and Saiz, {Luis Carlos} and Juan Erviti and Storeb{\o}, {Ole Jakob} and Christian Gluud and G{\o}tzsche, {Peter C} and J{\o}rgensen, {Karsten Juhl}",
note = "{\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2017",
doi = "10.1136/ebmed-2017-110716",
language = "English",
volume = "22",
pages = "143--147",
journal = "BMJ Evidence-Based Medicine",
issn = "2515-446X",
publisher = "BMJ Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

AU - Boesen, Kim

AU - Saiz, Luis Carlos

AU - Erviti, Juan

AU - Storebø, Ole Jakob

AU - Gluud, Christian

AU - Gøtzsche, Peter C

AU - Jørgensen, Karsten Juhl

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2017

Y1 - 2017

N2 - A Cochrane systematic review on immediate-release methylphenidate for adults with attention deficit hyperactivity disorder (ADHD) was withdrawn from the Cochrane Library on 26 May 2016 after substantial criticism of its methods and flawed conclusions. Retraction of scientific papers on this basis is unusual but can be necessary. We provide a summary of the criticism that led to the withdrawal. We detail the methodological flaws of the withdrawn Cochrane systematic review and general issues of bias and shortcomings of the included ADHD trials: cross-over designs compared with parallel-group designs, exclusion of participants with psychiatric comorbidity, absence of 'functional outcomes' and use of clinical outcomes with limited relevance, short trial duration and small trial populations, broken blinding caused by easily recognisable side effects, combining outcome assessments by trial investigators and participants, outcome reporting bias, poor evaluation of cardiovascular and psychiatric harms and conflicts of interest of trialists and systematic reviewers. The withdrawal of the Cochrane systematic review signals recognition of previous unreliable clinical ADHD research. We conclude that clinical trials of immediate-release methylphenidate in adults with ADHD are of very low quality. We urgently need well-conducted long-term trials free of bias to assess the benefits and harms of central stimulant treatment in adult ADHD.

AB - A Cochrane systematic review on immediate-release methylphenidate for adults with attention deficit hyperactivity disorder (ADHD) was withdrawn from the Cochrane Library on 26 May 2016 after substantial criticism of its methods and flawed conclusions. Retraction of scientific papers on this basis is unusual but can be necessary. We provide a summary of the criticism that led to the withdrawal. We detail the methodological flaws of the withdrawn Cochrane systematic review and general issues of bias and shortcomings of the included ADHD trials: cross-over designs compared with parallel-group designs, exclusion of participants with psychiatric comorbidity, absence of 'functional outcomes' and use of clinical outcomes with limited relevance, short trial duration and small trial populations, broken blinding caused by easily recognisable side effects, combining outcome assessments by trial investigators and participants, outcome reporting bias, poor evaluation of cardiovascular and psychiatric harms and conflicts of interest of trialists and systematic reviewers. The withdrawal of the Cochrane systematic review signals recognition of previous unreliable clinical ADHD research. We conclude that clinical trials of immediate-release methylphenidate in adults with ADHD are of very low quality. We urgently need well-conducted long-term trials free of bias to assess the benefits and harms of central stimulant treatment in adult ADHD.

U2 - 10.1136/ebmed-2017-110716

DO - 10.1136/ebmed-2017-110716

M3 - Review

VL - 22

SP - 143

EP - 147

JO - BMJ Evidence-Based Medicine

JF - BMJ Evidence-Based Medicine

SN - 2515-446X

IS - 4

ER -

ID: 195163390